Listed by the USPTO as AEDER, SEAN E
Tech Center 1600 • Art Units: 1600 1642 1652 1654 1671
This examiner grants 57% of resolved cases
AEDER, SEAN E is a USPTO patent examiner in tech center 1600 and art unit 1600. The profile covers 1438 resolved cases, with a 57.0% allowance rate and a median of 1124 days to allowance. The 19.8% interview lift indicates a higher observed allowance outcome for cases involving interviews.
The listed companies are Novartis AG, Bristol-Myers Squibb Company, and Biontech SE. The listed firms are CASIMIR JONES, S.C., EpiMED LLC, and Fox Rothschild, LLP. The large resolved-case record supports using the measures as meaningful prosecution context. The allowance rate indicates that applicants should prepare for substantive examination, while the interview result supports considering interviews as one component of response strategy.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18167295 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | Final Rejection | Genentech, Inc. |
| 18359569 | LDL RECEPTOR-DIRECTED BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS | Non-Final OA | The Regents of the University of California |
| 17918479 | TARGETING ABCB5 IN GLIOBLASTOMA MULTIFORME | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18683858 | OFATUMUMAB FOR TREATING PEDIATRIC MS | Non-Final OA | NOVARTIS AG |
| 17753632 | TREATMENT OF RMS BY SWITCHING THERAPY | Non-Final OA | Novartis AG |
| 18042441 | METHODS OF TREATING CANCER BY ADMINISTERING A PD-1 INHIBITOR | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18746198 | DETECTING NEOPLASM | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18720518 | METHODS OF USING AN ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY AND ANTI-TAU ANTIBODY | Non-Final OA | WASHINGTON UNIVERSITY |
| 17775233 | TARGETING CIRCULAR PCMTD1 IN LEUKEMIAS WITH P53 MUTATIONS AND/OR BCR/ABL FUSIONS | Final Rejection | Ohio State Innovation Foundation |
| 18284590 | MODULATING PRODUCT QUALITY OF ASYMMETRIC MULTISPECIFIC ANTIBODIES THROUGH THE USE OF TEMPERATURE | Non-Final OA | AMGEN INC. |
| 18030223 | ENHANCEMENT OF ANTI-TUMOR PHAGOCYTOSIS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18528327 | NATURAL KILLER T CELL LIGAND LOADED EXTRACELLULAR NANOVESICLE AND AUTOLOGOUS ANTI-CANCER VACCINE FOR HEMATOLOGIC MALIGNANCIES COMPRISING THE SAME | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18010580 | BIOMARKER BASED PATIENT SELECTION FOR PROTEASOME INHIBITOR TREATMENT | Non-Final OA | University of Utah Research Foundation |
| 18193917 | METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 17779716 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION | Non-Final OA | Cedars-Sinai Medical Center |
| 18463743 | TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS | Non-Final OA | Bristol-Myers Squibb Company |
| 17763614 | COMPOSITE BIOMARKER FOR CANCER THERAPY | Final Rejection | Bristol-Myers Squibb Company |
| 18247878 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 18558066 | NEUTRALIZING ANTI- SARS-COV-2 ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | The Rockefeller University |
| 17296506 | METHODS FOR TREATING DYSREGULATED LIPID METABOLISM | Final Rejection | DENALI THERAPEUTICS INC. |
| 18392902 | METHODS FOR DELIVERING ANTIBODIES TO THE FETAL CIRCULATION | Final Rejection | The Children's Medical Center Corporation |
| 18292232 | COMPOSITIONS AND METHODS FOR TREATMENT OF MELANOMA | Non-Final OA | BioNTech SE |
| 18549346 | MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN THERAPY | Non-Final OA | BIONTECH SE |
| 18402642 | ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES AND USES THEREOF | Non-Final OA | BioAtla, Inc. |
| 17781652 | USE OF CELL FREE NUCLEOSOMES AS BIOMARKERS | Final Rejection | Belgian Volition SRL |
| 18498508 | THERAPEUTIC METHODS AND USES FOR ANTIBODIES TO HUMAN MASP-3 | Final Rejection | Novo Nordisk Healthcare AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy57.0% of resolved applications examined by Sean E Aeder were allowed (1,438 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.
This examiner's interview lift is +19.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sean E Aeder took 1,124 days on average from filing to allowance.
Sean E Aeder examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).